SBRT in metastatic/advanced NSCLC to a single tumor site with a dose of 8 Gy in three doses with immunotherapy has been shown to increase the response rate of programmed death-ligand 1 (PDL-1) negative tumors in the PEMBRO-RT trial [19]. The gene discussed is CD274; the disease is neoplasm.